SG11202102492PA - Combination therapy for the treatment of prostate cancer - Google Patents
Combination therapy for the treatment of prostate cancerInfo
- Publication number
- SG11202102492PA SG11202102492PA SG11202102492PA SG11202102492PA SG11202102492PA SG 11202102492P A SG11202102492P A SG 11202102492PA SG 11202102492P A SG11202102492P A SG 11202102492PA SG 11202102492P A SG11202102492P A SG 11202102492PA SG 11202102492P A SG11202102492P A SG 11202102492PA
- Authority
- SG
- Singapore
- Prior art keywords
- erg
- compound
- prostate cancer
- androgen
- etv
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862730869P | 2018-09-13 | 2018-09-13 | |
| US201862737612P | 2018-09-27 | 2018-09-27 | |
| US201862778185P | 2018-12-11 | 2018-12-11 | |
| PCT/US2019/050970 WO2020056232A1 (en) | 2018-09-13 | 2019-09-13 | Combination therapy for the treatment of prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202102492PA true SG11202102492PA (en) | 2021-04-29 |
Family
ID=69778254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102492PA SG11202102492PA (en) | 2018-09-13 | 2019-09-13 | Combination therapy for the treatment of prostate cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220117942A1 (enExample) |
| EP (1) | EP3849544A4 (enExample) |
| JP (1) | JP7441214B2 (enExample) |
| KR (1) | KR102844523B1 (enExample) |
| CN (1) | CN112912075B (enExample) |
| AU (1) | AU2019338483B2 (enExample) |
| CA (1) | CA3112396A1 (enExample) |
| IL (1) | IL281281B2 (enExample) |
| MX (1) | MX2021002884A (enExample) |
| SG (1) | SG11202102492PA (enExample) |
| TW (1) | TWI816880B (enExample) |
| WO (1) | WO2020056232A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI882964B (zh) | 2018-09-13 | 2025-05-11 | 大陸商恒翼生物醫藥（上海）股份有限公司 | Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法 |
| EP4294397A1 (en) * | 2021-02-22 | 2023-12-27 | Celgene Quanticel Research, Inc. | Bromodomain (bet) inhibitor for use in treating prostate cancer |
| CN114644687B (zh) * | 2022-04-07 | 2023-06-27 | 华中科技大学同济医学院附属协和医院 | 一种可拮抗rbm25蛋白rna结合活性的多肽rbip-21及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| WO2012044577A1 (en) * | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
| KR102307566B1 (ko) * | 2013-06-21 | 2021-10-05 | 제니쓰 에피제네틱스 리미티드 | 신규한 바이사이클릭 브로모도메인 억제제 |
| EP3062808B1 (en) * | 2013-10-28 | 2021-09-29 | The Regents of the University of California | Treatment of metastatic prostate cancer |
| NO2719005T3 (enExample) * | 2014-07-28 | 2018-01-20 | ||
| WO2016171470A1 (en) * | 2015-04-21 | 2016-10-27 | Kainos Medicine, Inc. | Bromodomain-inhibiting compounds and methods to prevent or treat a cancer |
| US20190134004A1 (en) * | 2016-06-16 | 2019-05-09 | The University Of Chicago | Methods and compositions for treating breast and prostate cancer |
| WO2018097977A1 (en) * | 2016-11-22 | 2018-05-31 | Gilead Sciences, Inc. | Crystalline forms of a phosphate complex of a bet inhibitor |
| US20180153867A1 (en) * | 2016-12-06 | 2018-06-07 | Gilead Sciences, Inc. | Treatment of prostate cancer by concomitant administration of a bromodomain inhibitor and a second agent |
-
2019
- 2019-09-12 TW TW108133128A patent/TWI816880B/zh active
- 2019-09-13 EP EP19860912.5A patent/EP3849544A4/en active Pending
- 2019-09-13 WO PCT/US2019/050970 patent/WO2020056232A1/en not_active Ceased
- 2019-09-13 CN CN201980059904.2A patent/CN112912075B/zh active Active
- 2019-09-13 CA CA3112396A patent/CA3112396A1/en active Pending
- 2019-09-13 KR KR1020217010491A patent/KR102844523B1/ko active Active
- 2019-09-13 JP JP2021514070A patent/JP7441214B2/ja active Active
- 2019-09-13 SG SG11202102492PA patent/SG11202102492PA/en unknown
- 2019-09-13 AU AU2019338483A patent/AU2019338483B2/en active Active
- 2019-09-13 US US17/275,473 patent/US20220117942A1/en active Pending
- 2019-09-13 MX MX2021002884A patent/MX2021002884A/es unknown
- 2019-09-13 IL IL281281A patent/IL281281B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019338483A1 (en) | 2021-04-08 |
| CN112912075A (zh) | 2021-06-04 |
| EP3849544A1 (en) | 2021-07-21 |
| KR102844523B1 (ko) | 2025-08-12 |
| EP3849544A4 (en) | 2022-06-08 |
| MX2021002884A (es) | 2021-07-15 |
| WO2020056232A1 (en) | 2020-03-19 |
| CA3112396A1 (en) | 2020-03-19 |
| KR20210060515A (ko) | 2021-05-26 |
| IL281281B2 (en) | 2026-03-01 |
| TW202017926A (zh) | 2020-05-16 |
| IL281281B1 (en) | 2025-11-01 |
| IL281281A (en) | 2021-04-29 |
| US20220117942A1 (en) | 2022-04-21 |
| CN112912075B (zh) | 2023-04-04 |
| JP7441214B2 (ja) | 2024-02-29 |
| AU2019338483B2 (en) | 2025-01-02 |
| JP2022500431A (ja) | 2022-01-04 |
| TWI816880B (zh) | 2023-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281256A (en) | Combined treatment for the treatment of triple-negative breast cancer | |
| IL291844B1 (en) | smc combined therapy for cancer treatment | |
| IL267795A (en) | Combined treatment for cancer | |
| ZA202206743B (en) | Therapy for the treatment of cancer | |
| IL280337A (en) | LAG-3 combination therapy for cancer treatment | |
| SG11202103141YA (en) | Combination therapy for the treatment of cancer | |
| IL281439A (en) | Combined treatment for blood cancer | |
| IL282093B1 (en) | Combination therapy for cancer | |
| IL266993A (en) | Combined therapy for cancer treatment | |
| IL307465A (en) | Combined therapies for cancer treatment | |
| IL275949A (en) | Combined treatment for the treatment of cancer or its prevention | |
| IL263905A (en) | Combined cancer treatment | |
| IL276074A (en) | Combined treatment for the treatment of cancer or its prevention | |
| IL284162A (en) | Integrated healing for cancer treatment | |
| IL279591A (en) | Cancer treatment methods using combination therapy | |
| IL281281B2 (en) | Combination containing a bromodomain levothyroxine inhibitor for the treatment of prostate cancer | |
| IL276073A (en) | Combined treatment for the treatment of cancer or its prevention | |
| IL275981A (en) | Combined therapies for the treatment of hepatocellular carcinoma | |
| IL275860A (en) | Combined treatment for the treatment of cancer or its prevention | |
| SG11202100571TA (en) | Anti-lypd3 car t-cell therapy for the treatment of cancer | |
| IL253642A0 (en) | Combined treatment for cancer | |
| HK40061708A (en) | Combination therapy for the treatment of cancer | |
| HK40060019A (en) | Combination therapy for the treatment of cancer | |
| HK40059519A (en) | Combination therapy for treating metastatic prostate cancer | |
| HK40054677A (en) | Combination therapy for treating cancer |